Thẻ: keytruda

Advanced renal cell carcinoma treatment

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses the recent European Medicines Agency’s Committee for Medicinal Products for Human Use … source: Xem thêm các bài viết về Sức Khỏe:

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial

Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma (CSCC). Website: Twitter: Facebook: LinkedIn: source: …

MRK Stock | Merck & Co. Q1 2019 Earnings Call

KEYTRUDA helps Merck to report Q1 earnings beat, raises 2019 outlook April 30, 2019 Shares of the pharma giant Merck (MRK) rose 2% before the market hours after the company surpassed estimates on the headline numbers. The company’s strong results were powered by its blockbuster drug KEYTRUDA which …